225 related articles for article (PubMed ID: 19138958)
1. Combination chemoprevention of HER2/neu-induced breast cancer using a cyclooxygenase-2 inhibitor and a retinoid X receptor-selective retinoid.
Brown PH; Subbaramaiah K; Salmon AP; Baker R; Newman RA; Yang P; Zhou XK; Bissonnette RP; Dannenberg AJ; Howe LR
Cancer Prev Res (Phila); 2008 Aug; 1(3):208-14. PubMed ID: 19138958
[TBL] [Abstract][Full Text] [Related]
2. The retinoid X receptor-selective retinoid, LGD1069, down-regulates cyclooxygenase-2 expression in human breast cells through transcription factor crosstalk: implications for molecular-based chemoprevention.
Kong G; Kim HT; Wu K; DeNardo D; Hilsenbeck SG; Xu XC; Lamph WW; Bissonnette R; Dannenberg AJ; Brown PH
Cancer Res; 2005 Apr; 65(8):3462-9. PubMed ID: 15833882
[TBL] [Abstract][Full Text] [Related]
3. Celecoxib, a selective cyclooxygenase 2 inhibitor, protects against human epidermal growth factor receptor 2 (HER-2)/neu-induced breast cancer.
Howe LR; Subbaramaiah K; Patel J; Masferrer JL; Deora A; Hudis C; Thaler HT; Muller WJ; Du B; Brown AM; Dannenberg AJ
Cancer Res; 2002 Oct; 62(19):5405-7. PubMed ID: 12359744
[TBL] [Abstract][Full Text] [Related]
4. Suppression of mammary tumorigenesis in transgenic mice by the RXR-selective retinoid, LGD1069.
Wu K; Kim HT; Rodriquez JL; Hilsenbeck SG; Mohsin SK; Xu XC; Lamph WW; Kuhn JG; Green JE; Brown PH
Cancer Epidemiol Biomarkers Prev; 2002 May; 11(5):467-74. PubMed ID: 12010861
[TBL] [Abstract][Full Text] [Related]
5. The rexinoid, bexarotene, prevents the development of premalignant lesions in MMTV-erbB2 mice.
Li Y; Zhang Y; Hill J; Kim HT; Shen Q; Bissonnette RP; Lamph WW; Brown PH
Br J Cancer; 2008 Apr; 98(8):1380-8. PubMed ID: 18362934
[TBL] [Abstract][Full Text] [Related]
6. The cyclooxygenase-2 inhibitor, celecoxib, prevents the development of mammary tumors in Her-2/neu mice.
Lanza-Jacoby S; Miller S; Flynn J; Gallatig K; Daskalakis C; Masferrer JL; Zweifel BS; Sembhi H; Russo IH
Cancer Epidemiol Biomarkers Prev; 2003 Dec; 12(12):1486-91. PubMed ID: 14693742
[TBL] [Abstract][Full Text] [Related]
7. The retinoid X receptor-selective retinoid, LGD1069, prevents the development of estrogen receptor-negative mammary tumors in transgenic mice.
Wu K; Zhang Y; Xu XC; Hill J; Celestino J; Kim HT; Mohsin SK; Hilsenbeck SG; Lamph WW; Bissonette R; Brown PH
Cancer Res; 2002 Nov; 62(22):6376-80. PubMed ID: 12438218
[TBL] [Abstract][Full Text] [Related]
8. Bexarotene induces cellular senescence in MMTV-Neu mouse model of mammary carcinogenesis.
Shilkaitis A; Bratescu L; Green A; Yamada T; Christov K
Cancer Prev Res (Phila); 2013 Apr; 6(4):299-308. PubMed ID: 23430755
[TBL] [Abstract][Full Text] [Related]
9. Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor.
Rao CV; Indranie C; Simi B; Manning PT; Connor JR; Reddy BS
Cancer Res; 2002 Jan; 62(1):165-70. PubMed ID: 11782374
[TBL] [Abstract][Full Text] [Related]
10. Prevention of tumorigenesis in p53-null mammary epithelium by rexinoid bexarotene, tyrosine kinase inhibitor gefitinib, and celecoxib.
Medina D; Kittrell F; Hill J; Zhang Y; Hilsenbeck SG; Bissonette R; Brown PH
Cancer Prev Res (Phila); 2009 Feb; 2(2):168-74. PubMed ID: 19174577
[TBL] [Abstract][Full Text] [Related]
11. Steroid receptor coactivator 1 deficiency increases MMTV-neu mediated tumor latency and differentiation specific gene expression, decreases metastasis, and inhibits response to PPAR ligands.
Han JS; Crowe DL
BMC Cancer; 2010 Nov; 10():629. PubMed ID: 21080969
[TBL] [Abstract][Full Text] [Related]
12. Alteration in apoptosis and cell cycle by celecoxib and/or fish oil in 7,12-dimethyl benzene (α) anthracene-induced mammary carcinogenesis.
Negi AK; Kansal S; Bhatnagar A; Agnihotri N
Tumour Biol; 2013 Dec; 34(6):3753-64. PubMed ID: 24057882
[TBL] [Abstract][Full Text] [Related]
13. A short-term rat mammary carcinogenesis model for the prevention of hormonally responsive and nonresponsive in situ carcinomas.
Woditschka S; Haag JD; Sullivan R; Gould MN
Cancer Prev Res (Phila); 2009 Feb; 2(2):153-60. PubMed ID: 19196722
[TBL] [Abstract][Full Text] [Related]
14. HER-2/neu status is a determinant of mammary aromatase activity in vivo: evidence for a cyclooxygenase-2-dependent mechanism.
Subbaramaiah K; Howe LR; Port ER; Brogi E; Fishman J; Liu CH; Hla T; Hudis C; Dannenberg AJ
Cancer Res; 2006 May; 66(10):5504-11. PubMed ID: 16707480
[TBL] [Abstract][Full Text] [Related]
15. Neu-induced retroviral rat mammary carcinogenesis: a novel chemoprevention model for both hormonally responsive and nonresponsive mammary carcinomas.
Woditschka S; Haag JD; Waller JL; Monson DM; Hitt AA; Brose HL; Hu R; Zheng Y; Watson PA; Kim K; Lindstrom MJ; Mau B; Steele VE; Lubet RA; Gould MN
Cancer Res; 2006 Jul; 66(13):6884-91. PubMed ID: 16818667
[TBL] [Abstract][Full Text] [Related]
16. Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.
Bischoff ED; Heyman RA; Lamph WW
J Natl Cancer Inst; 1999 Dec; 91(24):2118. PubMed ID: 10601384
[TBL] [Abstract][Full Text] [Related]
17. Synergistic anticancer effects of combined gamma-tocotrienol and celecoxib treatment are associated with suppression in Akt and NFkappaB signaling.
Shirode AB; Sylvester PW
Biomed Pharmacother; 2010 May; 64(5):327-32. PubMed ID: 19954924
[TBL] [Abstract][Full Text] [Related]
18. Lack of efficacy of the statins atorvastatin and lovastatin in rodent mammary carcinogenesis.
Lubet RA; Boring D; Steele VE; Ruppert JM; Juliana MM; Grubbs CJ
Cancer Prev Res (Phila); 2009 Feb; 2(2):161-7. PubMed ID: 19196723
[TBL] [Abstract][Full Text] [Related]
19. Targeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth.
Mann M; Sheng H; Shao J; Williams CS; Pisacane PI; Sliwkowski MX; DuBois RN
Gastroenterology; 2001 Jun; 120(7):1713-9. PubMed ID: 11375952
[TBL] [Abstract][Full Text] [Related]
20. Changes associated with delay of mammary cancer by retinoid analogues in transgenic mice bearing c-neu oncogene.
Rao GN; Ney E; Herbert RA
Breast Cancer Res Treat; 1999 Dec; 58(3):241-54. PubMed ID: 10718486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
